Alterome Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.alterome.com
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1
Recruiting
- Conditions
- CancerCRC (Colorectal Cancer)PDAC - Pancreatic Ductal AdenocarcinomaAdvanced Solid TumorsNSCLC (Non-small Cell Lung Cancer)
- Interventions
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Alterome Therapeutics, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT06835569
- Locations
- 🇺🇸
Research Site, Fairfax, Virginia, United States
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Phase 1
Recruiting
- Conditions
- CancerBreast CancerEndometrial CancerMetastatic CancerAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Alterome Therapeutics, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06533059
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
🇺🇸Research Site #2, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath